vs
AVANOS MEDICAL, INC.（AVNS）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是PREFORMED LINE PRODUCTS CO的1.0倍（$180.9M vs $173.1M），PREFORMED LINE PRODUCTS CO净利率更高（4.9% vs -0.7%，领先5.6%），PREFORMED LINE PRODUCTS CO同比增速更快（3.6% vs 0.7%），AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $11.8M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
AVNS vs PLPC — 直观对比
营收规模更大
AVNS
是对方的1.0倍
$173.1M
营收增速更快
PLPC
高出2.9%
0.7%
净利率更高
PLPC
高出5.6%
-0.7%
自由现金流更多
AVNS
多$9.5M
$11.8M
两年增速更快
PLPC
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $173.1M |
| 净利润 | $-1.3M | $8.4M |
| 毛利率 | 47.5% | 29.8% |
| 营业利润率 | 1.4% | 6.8% |
| 净利率 | -0.7% | 4.9% |
| 营收同比 | 0.7% | 3.6% |
| 净利润同比 | 99.7% | -19.3% |
| 每股收益（稀释后） | $-0.02 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSPLPC
| Q4 25 | $180.9M | $173.1M | ||
| Q3 25 | $177.8M | $178.1M | ||
| Q2 25 | $175.0M | $169.6M | ||
| Q1 25 | $167.5M | $148.5M | ||
| Q4 24 | $179.6M | $167.1M | ||
| Q3 24 | $170.4M | $147.0M | ||
| Q2 24 | $171.7M | $138.7M | ||
| Q1 24 | $166.1M | $140.9M |
净利润AVNSPLPC
| Q4 25 | $-1.3M | $8.4M | ||
| Q3 25 | $-1.4M | $2.6M | ||
| Q2 25 | $-76.8M | $12.7M | ||
| Q1 25 | $6.6M | $11.5M | ||
| Q4 24 | $-397.3M | $10.5M | ||
| Q3 24 | $4.3M | $7.7M | ||
| Q2 24 | $1.8M | $9.4M | ||
| Q1 24 | $-900.0K | $9.6M |
毛利率AVNSPLPC
| Q4 25 | 47.5% | 29.8% | ||
| Q3 25 | 48.4% | 29.7% | ||
| Q2 25 | 52.6% | 32.7% | ||
| Q1 25 | 53.6% | 32.8% | ||
| Q4 24 | 54.6% | 33.3% | ||
| Q3 24 | 54.5% | 31.1% | ||
| Q2 24 | 55.7% | 31.9% | ||
| Q1 24 | 57.1% | 31.3% |
营业利润率AVNSPLPC
| Q4 25 | 1.4% | 6.8% | ||
| Q3 25 | 0.1% | 7.4% | ||
| Q2 25 | -42.6% | 10.1% | ||
| Q1 25 | 6.1% | 8.8% | ||
| Q4 24 | -233.0% | 10.5% | ||
| Q3 24 | 7.0% | 7.1% | ||
| Q2 24 | 3.7% | 8.1% | ||
| Q1 24 | 2.4% | 8.2% |
净利率AVNSPLPC
| Q4 25 | -0.7% | 4.9% | ||
| Q3 25 | -0.8% | 1.5% | ||
| Q2 25 | -43.9% | 7.5% | ||
| Q1 25 | 3.9% | 7.8% | ||
| Q4 24 | -221.2% | 6.3% | ||
| Q3 24 | 2.5% | 5.2% | ||
| Q2 24 | 1.0% | 6.8% | ||
| Q1 24 | -0.5% | 6.8% |
每股收益（稀释后）AVNSPLPC
| Q4 25 | $-0.02 | $1.72 | ||
| Q3 25 | $-0.03 | $0.53 | ||
| Q2 25 | $-1.66 | $2.56 | ||
| Q1 25 | $0.14 | $2.33 | ||
| Q4 24 | $-8.64 | $2.13 | ||
| Q3 24 | $0.09 | $1.54 | ||
| Q2 24 | $0.04 | $1.89 | ||
| Q1 24 | $-0.02 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | — |
| 总债务越低越好 | $90.3M | $38.3M |
| 股东权益账面价值 | $778.2M | $475.5M |
| 总资产 | $1.1B | $653.6M |
| 负债/权益比越低杠杆越低 | 0.12× | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资AVNSPLPC
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
总债务AVNSPLPC
| Q4 25 | $90.3M | $38.3M | ||
| Q3 25 | $93.4M | $36.0M | ||
| Q2 25 | $95.7M | $31.8M | ||
| Q1 25 | $98.0M | $29.1M | ||
| Q4 24 | $125.3M | $20.8M | ||
| Q3 24 | $152.6M | $27.2M | ||
| Q2 24 | $164.9M | $31.6M | ||
| Q1 24 | $167.2M | $55.0M |
股东权益AVNSPLPC
| Q4 25 | $778.2M | $475.5M | ||
| Q3 25 | $778.0M | $466.3M | ||
| Q2 25 | $776.3M | $460.7M | ||
| Q1 25 | $839.4M | $435.8M | ||
| Q4 24 | $828.5M | $422.3M | ||
| Q3 24 | $1.2B | $429.0M | ||
| Q2 24 | $1.2B | $416.2M | ||
| Q1 24 | $1.2B | $413.4M |
总资产AVNSPLPC
| Q4 25 | $1.1B | $653.6M | ||
| Q3 25 | $1.1B | $644.6M | ||
| Q2 25 | $1.0B | $631.5M | ||
| Q1 25 | $1.1B | $592.5M | ||
| Q4 24 | $1.2B | $573.9M | ||
| Q3 24 | $1.7B | $592.0M | ||
| Q2 24 | $1.7B | $572.6M | ||
| Q1 24 | $1.7B | $586.1M |
负债/权益比AVNSPLPC
| Q4 25 | 0.12× | 0.08× | ||
| Q3 25 | 0.12× | 0.08× | ||
| Q2 25 | 0.12× | 0.07× | ||
| Q1 25 | 0.12× | 0.07× | ||
| Q4 24 | 0.15× | 0.05× | ||
| Q3 24 | 0.12× | 0.06× | ||
| Q2 24 | 0.13× | 0.08× | ||
| Q1 24 | 0.14× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $11.8M |
| 自由现金流率自由现金流/营收 | 11.8% | 6.8% |
| 资本支出强度资本支出/营收 | 3.8% | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.60× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $33.3M |
8季度趋势，按日历期对齐
经营现金流AVNSPLPC
| Q4 25 | $28.2M | $21.9M | ||
| Q3 25 | $14.0M | $18.9M | ||
| Q2 25 | $6.8M | $26.9M | ||
| Q1 25 | $25.7M | $5.7M | ||
| Q4 24 | $57.9M | $24.1M | ||
| Q3 24 | $23.0M | $9.4M | ||
| Q2 24 | $27.8M | $28.3M | ||
| Q1 24 | $-8.0M | $5.8M |
自由现金流AVNSPLPC
| Q4 25 | $21.3M | $11.8M | ||
| Q3 25 | $7.0M | $8.3M | ||
| Q2 25 | $-4.2M | $18.6M | ||
| Q1 25 | $19.0M | $-5.3M | ||
| Q4 24 | $53.1M | $20.6M | ||
| Q3 24 | $20.0M | $5.8M | ||
| Q2 24 | $21.9M | $24.6M | ||
| Q1 24 | $-12.1M | $1.8M |
自由现金流率AVNSPLPC
| Q4 25 | 11.8% | 6.8% | ||
| Q3 25 | 3.9% | 4.7% | ||
| Q2 25 | -2.4% | 10.9% | ||
| Q1 25 | 11.3% | -3.6% | ||
| Q4 24 | 29.6% | 12.3% | ||
| Q3 24 | 11.7% | 3.9% | ||
| Q2 24 | 12.8% | 17.7% | ||
| Q1 24 | -7.3% | 1.3% |
资本支出强度AVNSPLPC
| Q4 25 | 3.8% | 5.9% | ||
| Q3 25 | 3.9% | 6.0% | ||
| Q2 25 | 6.3% | 4.9% | ||
| Q1 25 | 4.0% | 7.4% | ||
| Q4 24 | 2.7% | 2.1% | ||
| Q3 24 | 1.8% | 2.4% | ||
| Q2 24 | 3.4% | 2.7% | ||
| Q1 24 | 2.5% | 2.8% |
现金转化率AVNSPLPC
| Q4 25 | — | 2.60× | ||
| Q3 25 | — | 7.21× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | 3.89× | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | 5.35× | 1.22× | ||
| Q2 24 | 15.44× | 3.02× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PLPC
暂无分部数据
